Overview

• Alumis Q3 net loss widens to $110.8 mln from $93.1 mln a year ago

• Company reports $2.1 mln collaboration revenue for Q3 2025

• Operating expenses rise due to increased R&D and merger costs

Outlook

• Alumis expects topline Phase 3 ONWARD data in early Q1 2026

• Company anticipates Phase 2b LUMUS data in Q3 2026

• Alumis plans Phase 2 trial for A-005 in H1 2026

Result Drivers

• INCREASED R&D EXPENSES - Alumis attributes rise in R&D expenses to increased contract research and clinical trial costs, including for envudeucitinib

• MERGER COSTS - Alumis cites merger with ACELYRIN as contributing to increased general and administrative expenses

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Alumis Inc is $18.00, about 70.9% above its November 12 closing price of $5.24

Press Release: ID:nGNX7tkZXF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)